A Study of Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis

Phase 3 Completed 274 enrolled AbbVie Eisai Inc. · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess the efficacy and safety of adalimumab in Japanese subjects with moderately to severely active ulcerative colitis (UC).

Timeline

Start: 2009-02
Primary completion: 2011-05
Completion: 2013-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Adalimumab	Monoclonal antibody	40 mg	Subcutaneous

A Study of Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis

Summary

Timeline

Drugs

Indications